An 8-K filing disclosed a warrant exchange with Venrock Healthcare Capital Partners: Venrock surrendered 1 million common shares for no consideration and received pre-funded warrants for 1 million shares at a $0.001 exercise price with a 9.99% beneficial ownership cap. Post-exchange, Korro has 13.7 million common shares outstanding and pre-funded warrants for 4.1 million shares.
Analyst sentiment remains broadly positive. Twelve firms covering the stock show a Moderate Buy consensus with an average 12-month price target of $16.71, while a separate nine-analyst set shows 88% Buy or Strong Buy ratings. The stock traded at $11.49 on August 5, within a $10.92–$12.06 range.
What to Watch
A key unresolved question is whether the glutamine synthetase mechanism will translate into clinical proof of hyperammonemia reduction when KRRO-121 enters human trials later this year?
Sources: Source 1 · Source 2 · Source 3 · Source 4 · Source 5 · Source 6
